Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for Myelodysplastic Syndrome
138 locations incl. Berkeley
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT06577441·Phase 2·Recruiting